Meridian Bioscience (VIVO) and Its Rivals Head to Head Contrast

Meridian Bioscience (NASDAQ: VIVO) is one of 89 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Meridian Bioscience to related businesses based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Volatility and Risk

Meridian Bioscience has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Meridian Bioscience’s competitors have a beta of 1.11, meaning that their average stock price is 11% more volatile than the S&P 500.

Earnings and Valuation

This table compares Meridian Bioscience and its competitors gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Meridian Bioscience $200.77 million $32.22 million 28.53
Meridian Bioscience Competitors $1.03 billion $127.87 million 193.33

Meridian Bioscience’s competitors have higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Meridian Bioscience and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Meridian Bioscience 10.74% 17.07% 11.52%
Meridian Bioscience Competitors -128.91% -39.16% -10.28%

Analyst Recommendations

This is a summary of current ratings for Meridian Bioscience and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Meridian Bioscience 1 3 0 0 1.75
Meridian Bioscience Competitors 207 1276 2772 100 2.63

Meridian Bioscience presently has a consensus price target of $14.00, suggesting a potential downside of 3.78%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 5.76%. Given Meridian Bioscience’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Meridian Bioscience has less favorable growth aspects than its competitors.

Dividends

Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.4%. Meridian Bioscience pays out 98.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.8% and pay out 36.9% of their earnings in the form of a dividend.

Insider & Institutional Ownership

87.2% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 67.3% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 2.3% of Meridian Bioscience shares are owned by company insiders. Comparatively, 11.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Meridian Bioscience competitors beat Meridian Bioscience on 10 of the 15 factors compared.

About Meridian Bioscience

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply